Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00934440 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
A Phase 1 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00934440 is a Phase 1 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT00934440, a Phase 1 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
To identify the maximum tolerable dose and assess qualitative/quantitative toxicities in patients with advanced renal cell cancer treated with combination of 5-azacitidine and bevacizumab.
Interventions
- DRUG Bevacizumab
- DRUG Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00934440
The ClinicalTrials.gov registry entry for NCT00934440 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00934440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00934440 about?
NCT00934440 is a clinical study titled "A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma". To identify the maximum tolerable dose and assess qualitative/quantitative toxicities in patients with advanced renal cell cancer treated with combination of 5-azacitidine and bevacizumab.
What is the current status of trial NCT00934440?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00934440?
The interventions under investigation include: Bevacizumab (DRUG), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT00934440?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.